Teresa Del Giudice
Catanzaro, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Adjuvant immunotherapy in high-risk stage II melanoma: real-world outcomes from a large multicenter retrospective study.
Journal: Cancer immunology, immunotherapy : CII
Published: April 08, 2026
Clinical activity and safety of nivolumab in combination with ipilimumab in metastatic melanoma: findings from REALIPINIVO, a real-world study.
Journal: Frontiers in immunology
Published: November 03, 2025
Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥ 50%: real-world data from the Italian ATLAS registry.
Journal: The oncologist
Published: September 19, 2025
Do age and performance status matter? A systematic review and network meta-analysis of immunotherapy studies in untreated advanced/metastatic non-oncogene addicted NSCLC.
Journal: Frontiers in immunology
Published: May 25, 2025
Immune-related [18F]FDG PET findings in patients undergoing checkpoint inhibitors treatment: correlation with clinical adverse events and prognostic implications.
Journal: Cancer imaging : the official publication of the International Cancer Imaging Society
Published: August 19, 2024
Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in Southern Italy.
Journal: Frontiers in immunology
Published: September 05, 2023
The impact of PARP inhibitors in the whole scenario of ovarian cancer management: A systematic review and network meta-analysis.
Journal: Critical reviews in oncology/hematology
Published: June 20, 2023
Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade.
Journal: Journal for immunotherapy of cancer
Published: May 05, 2020
Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab.
Journal: Molecular and clinical oncology
Published: November 02, 2018
The Era of PARP inhibitors in ovarian cancer: "Class Action" or not? A systematic review and meta-analysis.
Journal: Critical reviews in oncology/hematology
Published: June 09, 2018
Effectiveness of a diode laser in addition to non-surgical periodontal therapy: study of intervention.
Journal: Annali di stomatologia
Published: July 11, 2015
Last Updated: 09/26/2026